Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.medidd.2020.100043 http://scihub22266oqcxt.onion/10.1016/j.medidd.2020.100043 C7227543!7227543!C7227543     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Drug+Discov 2020 ; 6 (ä): 100043 Nephropedia Template TP {{tp|p=C7227543|t=2020. COVID-19 lockdown: de-risking exit by protecting the lung with leukaemia inhibitory factor (LIF) |pdf=|usr=}}{{C7227543}} gab.com Text COVID-19 lockdown: de-risking exit by protecting the lung with leukaemia inhibitory factor (LIF) JO: Med Drug Discov http://www.kidney.de/pget.php?&tw=1&pmid=C7227543 #FOAvip There are two key needs in COVID-19 management: (i) to reduce SARS-CoV-2 viral infection rate; and (ii) to reduce death rate of those infected - the subject of this commentary. The current WHO estimated global mortality rate is 3.4% (March 2020) and the global death toll has now past 200,000 (April 2020). Without therapy the COVID-19 pandemic is escalating exponentially: from the first reported death in Wuhan China 10th January 2020, it took 91?days for the global death toll to pass 100,000 - then a further 16?days to reach 200,000. A vaccination program will take 1?2?years to roll out, once safety and efficacy is proven. Anti-virals are being sought mainly amongst repurposed drug candidates but also with combinatorial screening of libraries, for example to block virus binding angiotensin converting enzyme 2 (ACE2) - ACE2 providing the receptor on cells that allows viral entry. Cell-based approaches include stem cells and exosomes but these will never meet scale of need whilst also carrying risk of viral transmission if contaminated. Countries have introduced Population control with social distancing and lockdown to isolate individuals: this has reduced infectivity rate - ?R? - where R denotes the average number of people an infected person will spread the illness to. But, after lockdown, the virus remains: the probability of R increasing again is high.The new danger is exit from lockdown. Here, leukaemia inhibitory factor (LIF) represents an untapped resource to boost the lung's own resistance to developing COVID-19 - reducing risk of severe disease as nations cautiously leave lockdown to return to normality. Twit Text FOAVip COVID-19 lockdown: de-risking exit by protecting the lung with leukaemia inhibitory factor (LIF) ????Med Drug Discov http://www.kidney.de/pget.php?&tw=1&pmid=C7227543 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=C7227543 #FOAvip English Wikipedia <ref>{{Cite pmid|C7227543}}</ref> COVID-19 lockdown: de-risking exit by protecting the lung with leukaemia inhibitory factor (LIF) #MMPMIDC7227543 Metcalfe SM Med Drug Discov 2020[Jun]; 6 (ä): 100043 PMIDC7227543show ga There are two key needs in COVID-19 management: (i) to reduce SARS-CoV-2 viral infection rate; and (ii) to reduce death rate of those infected - the subject of this commentary. The current WHO estimated global mortality rate is 3.4% (March 2020) and the global death toll has now past 200,000 (April 2020). Without therapy the COVID-19 pandemic is escalating exponentially: from the first reported death in Wuhan China 10th January 2020, it took 91?days for the global death toll to pass 100,000 - then a further 16?days to reach 200,000. A vaccination program will take 1?2?years to roll out, once safety and efficacy is proven. Anti-virals are being sought mainly amongst repurposed drug candidates but also with combinatorial screening of libraries, for example to block virus binding angiotensin converting enzyme 2 (ACE2) - ACE2 providing the receptor on cells that allows viral entry. Cell-based approaches include stem cells and exosomes but these will never meet scale of need whilst also carrying risk of viral transmission if contaminated. Countries have introduced Population control with social distancing and lockdown to isolate individuals: this has reduced infectivity rate - ?R? - where R denotes the average number of people an infected person will spread the illness to. But, after lockdown, the virus remains: the probability of R increasing again is high.The new danger is exit from lockdown. Here, leukaemia inhibitory factor (LIF) represents an untapped resource to boost the lung's own resistance to developing COVID-19 - reducing risk of severe disease as nations cautiously leave lockdown to return to normality. äCOVID-19 lockdown: de-risking exit by protecting the lung with leukaem(epmc).pdf DeepDyve Pubget Overpricing